Refractory anemia with ring sideroblasts.

Area of Science:

• Hematology
• Molecular Biology
• Genetics

Background:

• Refractory anemia with ring sideroblasts (RARS) is a myelodysplastic syndrome (MDS) subtype defined by ≥15% ring sideroblasts in bone marrow.
• Ring sideroblasts contain mitochondrial iron granules, and their molecular basis was previously unknown.
• SF3B1 mutations were identified in MDS with ring sideroblasts, establishing the first gene-MDS morphological feature link.

Purpose of the Study:

• To elucidate the molecular underpinnings of myelodysplastic syndromes with ring sideroblasts.
• To establish the causal relationship between SF3B1 mutations and the presence of ring sideroblasts.
• To differentiate the clinical implications of RARS, RCMD-RS, and RARS-T.

Main Methods:

• Whole exome sequencing studies were employed to identify somatic mutations.
• Perls staining was used to define and quantify ring sideroblasts based on siderotic granule presence and distribution.
• Clinical and morphological features of different MDS subtypes were analyzed.

Main Results:

• Somatic mutations in SF3B1, a gene crucial for RNA splicing, were found in patients with myelodysplasia with ring sideroblasts.
• SF3B1 mutations are strongly associated with the presence of ring sideroblasts, indicating a causal link.
• Refractory anemia with ring sideroblasts (RARS) typically presents with anemia and a benign course, while RCMD-RS carries a higher risk of bone marrow failure and AML progression. RARS-T involves thrombocytosis and potential progression from RARS.

Conclusions:

• SF3B1 mutations are the first identified genetic cause associated with a specific morphological feature in MDS.
• Understanding SF3B1's role provides insight into RARS pathogenesis and potential therapeutic targets.
• Distinguishing between RARS, RCMD-RS, and RARS-T is critical for prognostication and management due to differing clinical outcomes and risks.